C
Chunlin Li
Researcher at Chinese PLA General Hospital
Publications - 30
Citations - 288
Chunlin Li is an academic researcher from Chinese PLA General Hospital. The author has contributed to research in topics: Type 2 Diabetes Mellitus & Metformin. The author has an hindex of 9, co-authored 30 publications receiving 227 citations.
Papers
More filters
Journal ArticleDOI
Long-term efficacy and safety of sodium-glucose cotransporter-2 inhibitors as add-on to metformin treatment in the management of type 2 diabetes mellitus: A meta-analysis.
TL;DR: As add-on to metformin treatment, S GLT2 inhibitors are found significantly more efficacious than non-SGLT2 inhibitor combinations in the management of type 2 diabetes mellitus, although, SGLT 2 inhibitor therapy is associated with significantly higher incidence of suspected or confirmed genital tract infections.
Journal ArticleDOI
Assessment of Insulin Resistance in Subjects with Normal Glucose Tolerance, Hyperinsulinemia with Normal Blood Glucose Tolerance, Impaired Glucose Tolerance, and Newly Diagnosed Type 2 Diabetes (Prediabetes Insulin Resistance Research)
TL;DR: IR existed in the HINS, IGT, and T2DM groups, and IR levels were consistent in the three groups, suggesting that simple insulin sensitivity indices, especially Matsuda and Gutt index, were significantly associated with the M value.
Journal ArticleDOI
The effect of age on the changes in bone mineral density and osteoporosis detection rates in Han Chinese men over the age of 50.
TL;DR: Bilateral femoral neck BMD measurement can improve detection rates of OP and OSTA is a useful screening tool for OP in Han Chinese men over 50 years.
Journal ArticleDOI
Outcome of intensive integrated intervention in participants with impaired glucose regulation in China.
TL;DR: Intensive integrated intervention may significantly decrease the conversion rate of IGR to T2DM, and increase the conversion ratio to normal glucose tolerance, and the increase of waist circumference or SBP and the deterioration of islet beta cell function may be important risk factors for progression from prediabetes to diabetes.
Journal ArticleDOI
Efficacy and safety of sodium-glucose cotransporter 2 inhibitors as add-on to metformin and sulfonylurea treatment for the management of type 2 diabetes: a meta-analysis.
TL;DR: Treatment with SGLT2 inhibitors as add-on to metformin and sulfonylurea treatment for type 2 diabetes management was associated with significant reductions in blood pressure and triglycerides and increase in high-density lipoprotein-cholesterol.